Pedro Corzo
Internal Medicine · Corona, NYNPI 1275699852
Payments from drug & device makers
Across 219 payments — averaging $48.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- Amgen$1K
- Novo Nordisk$660
- Bayer$629
- Gilead$525
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,504100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $2,802 |
| AbbVie(2 entities) | 18 | $1,502 |
| Amgen(2 entities) | 24 | $1,180 |
| Novo Nordisk | 21 | $660 |
| Bayer | 11 | $629 |
| Gilead | 4 | $525 |
| Merck | 11 | $455 |
| Lilly USA, LLC | 10 | $330 |
| Boehringer Ingelheim | 11 | $321 |
| Amarin Pharma, Inc. | 11 | $282 |
| IBSA Pharma Inc. | 2 | $250 |
| Johnson & Johnson | 4 | $198 |
| Exact Sciences | 7 | $187 |
| GSK | 2 | $176 |
| Intra-sana Laboratories | 4 | $160 |
| Zealand Pharma US, Inc. | 2 | $137 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Xeris Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $110 |
| Novartis | 5 | $97 |
| Neurocrine Biosciences, Inc. | 3 | $85 |
| Ardelyx, Inc. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 2 | $56 |
| Pfizer | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,518 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 266 | $270,091 |
| FarxigaDapagliflozin Propanediol | 170 | $147,662 |
| JanuviaSitagliptin Phosphate | 93 | $109,039 |
| OzempicSemaglutide | 72 | $75,784 |
| TrulicityDulaglutide | 51 | $65,703 |
| LinzessLinaclotide | 106 | $56,866 |
| XareltoRivaroxaban | 71 | $54,855 |
| EliquisApixaban | 72 | $53,456 |
| VascepaIcosapent Ethyl | 100 | $46,323 |
| KerendiaFinerenone | 31 | $19,034 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 48 | $17,664 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $16,220 |
| EntrestoSacubitril/Valsartan | 12 | $14,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,137 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 83 | $11,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $321 | $270,091266 claims |
| AstraZenecaFarxiga | $2,802 | $147,662170 claims |
| MerckJanuvia, Janumet | $455 | $125,259112 claims |
| Novo NordiskOzempic | $660 | $75,78472 claims |
| Lilly USA, LLCTrulicity | $330 | $65,70351 claims |
| AbbVieLinzess | $1,502 | $56,866106 claims |
| Johnson & JohnsonXarelto | $198 | $54,85571 claims |
| PfizerEliquis | $38 | $53,45672 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $176 | $27,11959 claims |
| BayerKerendia | $629 | $19,03431 claims |
| NovartisEntresto | $97 | $14,30112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Corona
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.